Gts Securities LLC Cassava Sciences Inc Put Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 13, 2024	BUY	$9.57 - $35.08 $820,149 - $3.01 Million	85,700 Added 266.98%	117,800 $3.47 Million
Q2 2024 Aug 14, 2024	SELL	$12.35 - $26.11 $142,025 - $300,265	-11,500 Reduced 26.38%	32,100 $396,000
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $295,040 - $422,560	-16,000 Reduced 26.85%	43,600 $884,000
Q4 2023 Feb 14, 2024	BUY	$12.64 - $30.11 $50,560 - $120,440	4,000 Added 7.19%	59,600 $1.34 Million
Q3 2023 Nov 15, 2023	BUY	$16.64 - $25.32 $925,184 - $1.41 Million	55,600 New	55,600 $925,000

205

13.9M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $113M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.